BidaskClub upgraded shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) from a sell rating to a hold rating in a report published on Friday.

Several other research analysts have also recently issued reports on the company. ValuEngine upgraded Adaptimmune Therapeutics PLC from a strong sell rating to a sell rating in a research note on Thursday, July 20th. Cowen and Company restated a buy rating on shares of Adaptimmune Therapeutics PLC in a research note on Tuesday, June 6th. Finally, Zacks Investment Research upgraded Adaptimmune Therapeutics PLC from a hold rating to a buy rating and set a $5.25 price objective for the company in a research note on Wednesday, July 12th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. Adaptimmune Therapeutics PLC currently has an average rating of Hold and a consensus price target of $12.08.

Adaptimmune Therapeutics PLC (ADAP) opened at 5.21 on Friday. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $8.36.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, meeting analysts’ consensus estimates of ($0.24). Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. The company had revenue of $3.52 million during the quarter, compared to analysts’ expectations of $5.43 million. On average, equities research analysts expect that Adaptimmune Therapeutics PLC will post ($1.06) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Adaptimmune Therapeutics PLC (ADAP) Raised to Hold at BidaskClub” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/28/adaptimmune-therapeutics-plc-adap-raised-to-hold-at-bidaskclub.html.

Several hedge funds and other institutional investors have recently made changes to their positions in ADAP. Matrix Capital Management Company LP purchased a new position in shares of Adaptimmune Therapeutics PLC during the second quarter valued at about $39,027,000. NEA Management Company LLC boosted its position in shares of Adaptimmune Therapeutics PLC by 21.7% in the first quarter. NEA Management Company LLC now owns 12,025,999 shares of the biotechnology company’s stock valued at $66,263,000 after buying an additional 2,145,000 shares during the last quarter. AXA purchased a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at about $4,959,000. Tekla Capital Management LLC boosted its position in shares of Adaptimmune Therapeutics PLC by 158.9% in the first quarter. Tekla Capital Management LLC now owns 1,466,368 shares of the biotechnology company’s stock valued at $8,080,000 after buying an additional 900,000 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at about $2,883,000. Hedge funds and other institutional investors own 68.01% of the company’s stock.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Analyst Recommendations for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.